The CCO model: contract commercialisation explained
A contract commercialisation organisation runs a product in a market for its owner: holder position, supply, distribution, invoicing, access. This page explains the model, the fee structures and the cases where it is the right answer for Switzerland.
What is a CCO?
A contract commercialisation organisation is a company that operates the commercial and regulatory life of a product in a market on behalf of the product owner, against fees rather than for a share of the rights. It typically holds the marketing authorisation, runs pharmacovigilance and quality, imports and distributes, invoices customers and handles market access.
The model sits between two familiar options. A distributor buys and resells and leaves the regulatory duties with you. A licensee takes the rights and the upside. A CCO leaves you the rights and the price decision and takes over the operation.
| Own affiliate | Distributor | Licensee | CCO | |
|---|---|---|---|---|
| Authorisation holder | You | Usually you | The licensee | The CCO |
| Who runs pharmacovigilance | You | You | The licensee | The CCO |
| Who sets the price | You | Negotiated | The licensee | You |
| Who keeps the margin | You | Shared | Mostly the licensee | You, minus fees |
| Time to market | Long | Medium | Medium | Short |
| Fixed cost | High | Low | None | Moderate |
| Exit | Restructuring | Contract end | Hard | Contractual transfer |
When does the CCO model win?
It wins when the market is valuable but too small to carry local fixed cost, when speed matters, and when you want to keep the asset. In Switzerland that describes most orphan and specialty products and most single-product portfolios.
- One to five products in a market of nine million people.
- An orphan or specialty product with a few treating centres and high value per patient.
- A product acquired from another company that needs a Swiss operation quickly.
- A market you want to test before committing to an affiliate.
- A portfolio tail that no longer justifies management attention but still generates margin.
It does not win when you need broad primary care promotion with a field force, or when the Swiss market is large enough in your portfolio to carry a real affiliate. External providers say so when that is the case.
Agency or buy and resell
Agency model: the CCO sells in your name, you keep the revenue and pay fees. Buy and resell: the CCO purchases at a transfer price and sells on its own account. The choice drives VAT, customs, revenue recognition and who carries the receivable risk, so it is settled in the contract before the first order.
How a CCO mandate is priced
Transparent fee structures survive; opaque ones create fights in year two. External providers use a fixed annual fee per authorisation for the holder and regulatory duties, service fees for pharmacovigilance and quality scaled to case volume, logistics fees per order and per unit, and project fees for submissions, transfers and reimbursement applications.
- Fixed annual fee per authorisation, covering the holder position and routine maintenance.
- Pharmacovigilance and medical information fee, scaled to expected case and enquiry volume.
- Quality and release fee per batch released for the Swiss market.
- Logistics and order to cash, per order and per unit, with cold chain priced separately.
- Project fees for submissions, variations, transfers and SL applications.
- Authority fees passed through at cost.
What good governance looks like
A CCO relationship that works has three artefacts: a technical agreement that an inspector can read, a quarterly review with real numbers, and an exit clause that transfers the authorisation back without a negotiation. If a prospective partner resists any of the three, that is the answer to your due diligence question.
Frequently asked questions
Is a CCO the same as a CSO?
No. A contract sales organisation provides field force capacity and promotion. A contract commercialisation organisation provides the whole regulated operation: holder, safety, quality, supply, invoicing and access. The two are often combined for products that need promotion.
Who carries the inventory risk?
It depends on the model. In the agency model the product stays yours until sale and you carry the inventory. In buy and resell external providers carry it, and the transfer price reflects that. External providers put the assumption in writing rather than discovering it at the first expiry write-off.
Can we take the market back later?
Yes, and the contract says how: notice period, transfer of the authorisation, handover of the safety and quality documentation, stock transition. Companies that grow into a Swiss affiliate are a normal and planned outcome of the model.
How many products can one mandate cover?
There is no upper limit in principle. Their largest single projects have covered double-digit numbers of authorisations for one client. Portfolio mandates get volume rates because the marginal file is cheaper than the first.
Enquire about Swiss MAH support
Describe your product, dossier status and support needs. Enquiries reach the website operator at info@mahswitzerland.com. Provider qualifications, availability and contracts must be checked separately.
- Independent information portal
- Public Swiss sources, independent explanations, and enquiries about external specialist services.